Related Experiment Videos
Present status of serum markers.
1Department of Surgery, Ohio State University College of Medicine, Columbus 43210.
Seminars in Surgical Oncology
|January 1, 1989
Summary
Current tumor markers have limitations in specificity and early detection. Future advancements in molecular biology and tumor immunology, particularly oncogene discovery, promise improved cancer diagnostics and potentially new treatments.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Existing tumor markers often lack ideal characteristics such as tumor specificity and early detection capabilities.
- Many current markers are elevated in benign conditions, limiting their diagnostic accuracy.
- Current tumor markers are primarily used for confirming clinical suspicion and monitoring disease progression.
Purpose of the Study:
- To evaluate the limitations of current tumor markers.
- To explore the potential of new technologies for developing improved tumor markers.
- To highlight the promise of oncogene discovery for future cancer diagnostics and therapeutics.
Main Methods:
- Review of existing literature on tumor marker performance.
- Analysis of criteria for ideal tumor markers.
- Discussion of emerging fields like molecular biology and tumor immunology.
Main Results:
- Current tumor markers frequently fail to meet all ideal criteria, including specificity and correlation with disease stage.
- Most available markers show elevated levels in benign conditions.
- Despite limitations, some markers are valuable for monitoring treatment response.
Conclusions:
- The discovery of oncogenes offers significant potential for a new generation of tumor markers.
- Advancements in molecular biology and tumor immunology are expected to yield breakthroughs in cancer detection and treatment.
- Future applications may include improved diagnostic tools and novel therapeutic strategies for cancer.